new weight loss drug retatrutide Promises Big Loss, but Safety Remains a Question New GLP-1 obesity drug, retatrutide,

By dissolving under the tongue, the glutathione is delivered more directly into the systemic circulation, potentially allowing for quicker onset of action and increased bioavailability compared to traditional oral dosage forms

Recent studies have suggested the potential benefits of SGLT2 inhibitors, including empagliflozin, in slowing the progression of chronic kidney disease (CKD) in patients with type 2 diabetes, and reducing the risk of cardiovascular events.The decision to use empagliflozin in CKD should be made on a case-by-case basis, considering the patients overall kidney function and potential risks

Lean protein sources should form the foundation of your meals

Her new book The Savvy Womans Guide to Menopause: Before, During, and Beyond will be published by Johns Hopkins University Press in 2025

Only the best quality ingredients sourced from approved suppliers pass our rigorous vetting process prior to being used in production